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A study was undertaken to examine the population structure of viridans group streptococci (VGS) in the sputum of adult patients with cystic
fibrosis (CF). Freshly expectorated sputa (n=58) from 45 adult CF patients were examined by selective conventional culture on Mitis–Salivarius
agar and yielded 190 isolates of VGS. Sequence analyses of the rpnB and 16-23S rRNA ITS genes identified these isolates to belong to 12 species
of VGS and included S. anginosus, S. australis, S. cristatus, S. gordonii, S. infantis, S. mitis, S. mutans, S. oralis, S. parasanguinis,
S. pneumoniae, S. salivarius and S. sanguinis. The most frequently VGS organism isolated was S. salivarius (47/190; 24.7%), followed by S. mitis
(36/190; 19%), S. sanguinis (25/190; 13.2%), S. oralis (20/190; 11.0%), S. pneumoniae (19/190; 10.0%), S. parasanguinis (16/190; 8.4%),
S. infantis (11/190; 5.8%), S. gordonii (7/190; 3.7%), S. anginosus (4/190; 2.1%), S. cristatus (2/190; 1.1%), S. australis (1/190; 0.5%), S. mutans
(1/190; 0.5%) and S. agalactiae (1/190; 0.5%). All, but four, patients harboured at least one VGS species, which ranged from one to five
streptococcal species, with a mean of 2.85 species per patient. There was no clonality at the subspecies level employing ERIC RAPD PCR.
Antibiotic susceptibility was determined by Minimum Inhibitory Concentration (MIC) testing against penicillin, erythromycin and ciprofloxacin.
Overall, resistance to penicillin with all VGS was 73/190 (38.4%) and 167/190 (87.9%) for erythromycin. With regard to ciprofloxacin, 27/190
(14.2%) were fully resistant, whilst a further 21/190 (11.1%) showed intermediate resistance, which equated to approximately three quarters
(74.7%) of isolates being fully sensitive to this agent. In addition, as a comparator control population, we examined antibiotic susceptibility, as
above, in a non-CF population comprising 12 individuals (50 VGS isolates), who were not receiving chronic antibiotics. In comparison, 8% and
38% of VGS isolates from non-CF individuals were resistant by disk susceptibility testing to penicillin and erythromycin, respectively. None of
the non-CF VGS organisms were resistant to ciprofloxacin, but 42% showed intermediate resistance.
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Oral streptococci are largely composed of members of the
viridans group streptococci (VGS), which currently encom-
passes 20 species, which are commensal inhabitants of thed by Elsevier B.V. All rights reserved.
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of mammals [1]. On the basis of 16S rRNA sequence
homology, these bacteria are categorized in four groups: the
salivarius rRNA homology group, including Streptococcus
thermophilus, Streptococcus vestibularis and Streptococcus
salivarius; the mitis group, including Streptococcus cristatus,
Streptococcus gordonii, Streptococcus oralis, Streptococcus
mitis, Streptococcus pneumoniae, Streptococcus sanguinis and
Streptococcus parasanguinis; the anginosus group, including
Streptococcus anginosus, Streptococcus constellatus and Strep-
tococcus intermedius; and the mutans group, including
Streptococcus mutans, Streptococcus criceti, Streptococcus
downei, Streptococcus ferus, Streptococcus macacae, Strepto-
coccus ratti and Streptococcus sobrinus [1].
Historically, VGS organisms were not considered first line
pathogens of the immunocompetent host, with the exception of
VGS involvement in infective endocarditis. Recently, several
groups have reported on the clinical significance of bacterial
genera, which until now, were not regarded as important in the CF
lung pathology setting, including the anaerobes [2] and the
Streptococcus milleri Group [3]. Current opinion suggests that
these novel groups may play a crucial role in maintaining a stable
microbial ecology within the CF lung, and enhance virulence
associated with polymicrobial interactions, as well as directly
contributing to the pathology of the lung. However, to date, there
have been no reports on the ecological structure, distribution,
virulence, clinical role and frequency of viridans group streptococci
(VGS), which are known to act both as commensal bacteria, as well
as opportunistic pathogens, inCF sputum.Therefore, the aimof this
study was to investigate distribution and frequency of VGS and
pneumococci in CF sputum, as well as to determine their antibiotic
susceptibility, genetic relatedness and cytotoxic effects on epithelial
cells.2. Materials and methods
2.1. Bacterial isolates
In this study, 58 sputa from 45 adult CF patients attending the
Northern Ireland Regional Adult Cystic Fibrosis Unit at Belfast
City Hospital were examined culturally by conventional microbi-
ological techniques for the presence of VGS organisms and
pneumococci. Fresh expectorated sputa were collected from
patients by physiotherapists following either in-patient or out-
patient physiotherapy procedures. All sputa were plated onto
selective Mitis–Salivarius agar (cat no: 229810, Becton Dickinson
Ltd., Oxford, UK) containing 1% [w/v] tellurite solution and were
incubated for 48 h at 37 °C under microaerophilic conditions in a
CO2 incubator regulated at 5%[v/v] CO2. Following incubation for
48 h, presumptive VGS isolates resembling small and minute blue
colonies, as well as “gum drop”-like blue colonies and visually
distinct morphological variants, were subcultured onto Columbia
Blood agar (CM0331 Oxoid Ltd., Basingstoke, UK), supplemen-
ted with 5% (v/v) defibrinated horse blood for 24 h at 37 °C under
microaerophilic conditions, as detailed above. All isolates were
subsequently frozen in defibrinated horse blood (2 ml) at −80 °Cand stored as part of the Northern Ireland Public Health Laboratory
(NIPHL) Strain Repository.2.2. Molecular identification
Purified isolates were subcultured on Columbia Blood Agar, as
detailed above, for 24 h at 37 °C. All DNA isolation procedures
were carried out in a Class II Biological Safety Cabinet (Micro-
Flow, UK) in a room physically separated from that used to set up
nucleic acid amplification reaction mixes and also from the “post-
PCR” room in accordance with the Good Molecular Diagnostic
Procedures (GMDP) guidelines of Millar et al. [4], in order to
minimise contamination and hence the possibility of false positive
results. Bacterial genomicDNAwas extracted from few colonies of
each purified isolate, by employment of the Roche High Purity
PCR Template Preparation Kit (Roche Diagnostics Ltd., Sussex,
UK), in accordance with the manufacturer's instructions. Extracted
DNA was stored at −20 °C prior to PCR amplification. Two gene
loci were employed to identify theVGS to the species level, namely
the rnpB gene [5] and the 16S-23S rDNA ITS [6]. Following PCR
amplification, amplicons for sequencing were purified with a
QIAquick PCR purification kit (Qiagen Ltd., UK) and eluted in
Tris–HCl (10 mM, pH 8.5) prior to sequencing. Following
labelling of PCR amplicons using Big Dye cycle sequencing
chemistry (ABI, Applied Biosystems Ltd., Warrington, UK),
automated sequencing was performed on an ABI Capillary
Sequencer (3740 platform). Resulting sequences were confirmed
from chromatogram analysis and confirmed sequences were
compared with those stored in the GenBank using the BLASTn
alignment software (http://www.blast.genome.ad.jp/).2.3. Serotyping of pneumococcal isolates
All isolates which were identified molecularly as pneumo-
cocci were serotyped conventionally by a latex aggregation
assay (Pneumotest-Latex) (Statens Serum Institut, Copenhagen,
Denmark).2.4. Determination of antimicrobial susceptibility
Antibiotic susceptibility testing was performed on all VGS
isolates by standard disk susceptibility, as well as by
determination of the minimum inhibitory concentration (MIC)
value, against three classes of antibiotics, namely a β-lactam
(penicillin), a macrolide (erythromycin) and a fluoroquinolone
(ciprofloxacin). The MIC against the same agents was
determined by broth microdilution method according to CLSI
standard method [7]. In order to estimate ciprofloxacin
resistance, interpretive criteria for ofloxacin was used. Lyophi-
lised antimicrobial tablets were purchased from MAST Ltd.
(Merseyside, UK). In addition, as a comparator control
population, we examined antibiotic susceptibility, as above, in
a non-CF population comprising 12 individuals (50 VGS
isolates), who were not receiving chronic antibiotics.
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Genomic DNA was subjected to enterobacterial repetitive
intergenic consensus (ERIC)-PCR. PCR reaction mixes (25 μl)
contained: 2 μl of DNA template, containing circa. 50 ng DNA,
10 mM Tris–HCl, pH 8.3, 50 mM KCl, 1.8 mMMgCl2, 200 μM
of each dNTP, 1.5 U of Taq DNA polymerase (New England
Biolabs Ltd., Hertfordshire, UK) and 100 μM of each primer. The
primers ERIC 1R (5'-ATGTAAGCTCCTGGGGATTCAC-3')
and ERIC2 (5'-AAG TAA GTG ACT GGG GTG AGC G-3')
were previously described [8]. Reactionmixtures were subjected to
the following thermal cycling parameters in a GeneAmp 9700
thermal Cycler (Applied Biosystems, Warrington, UK): 95 °C for
5 min followed by 35 cycles of 95 °C for 45 s, annealing
temperature 52 °C for 1 min, 72 °C for 5 min, followed by a
final extension at 72 °C for 20 min. Following amplification, PCR
products were visualized on 1.5% (w/v) Certified LowRange Ultra
Agarose (Bio-Rad Laboratories Ltd., Hertfordshire, UK) contain-
ing ethidium bromide (1 μg/ml). Gels were analysed by UV
illumination with a gel image analysis system (UVP Products Ltd.,
Cambridge, UK) and banding profiles were determined manually,
where a unique genotype was defined as having one or greater
differences in its banding profile.2.6. Determination of VGS-related cytotoxicity
Cytotoxicity of the 13 species of streptococci isolated from adult
CF sputa (S. agalactiae, S. anginosus, S. australis, S. cristatus, S.S. agalactiae
S. mutans
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Fig. 1. Distribution and frequency of eagordonii, S. infantis, S. mitis, S. mutans, S. oralis, S. parasanguinis,
S. pneumoniae, S. salivarius& S. sanguinis) was assessed, as well
as Pseudomonas aeruginosaNCTC10662. A single representative
isolate of each species was randomly selected and was cultured
individually in 10 ml of Brain Heart Infusion (BHI) broth
(CM1032, Oxoid Ltd., UK), supplemented with yeast extract
(5 g/l; LP0021, Oxoid Ltd., UK) at 37 °C under microaerophilic
conditions for 24 h. Following this, 25 ml of fresh sterile BHIYE
broth were inoculated with 1 ml of pre-culture and incubated at
37 °C under microaerophilic conditions for 48 h. After incubation,
spent culture broth was filtered using a 0.22 μm syringe filter
(Millipore, Watford, UK). For cytotoxicity testing, filtered spent
broth (33 μl) was added to CF bronchial epithelial (CFBE) cell
suspension (66 μl≅5×104 cells) and incubated at 37 °C with 5%
[v/v] CO2 for 24 h. Cytotoxicity was measured by release of lactate
dehydrogenase (LDH) employing the LDH-CytotoxicityAssayKit
II (Bio Vision, California, USA) and plate reader (450 nm), as per
the manufacturer's instructions. % cytotoxicity was defined as:–
Cytotoxicity %ð Þ = Test sample−Low controlð Þ
High Control−Low Controlð Þ × 100
3. Results
3.1. Species identification and distribution
From the 58 sputa from 45 adult CF patients examined, 190
VGS isolates were cultured. Twelve members of the viridans19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
Patient
4 5 6
r of VGS isolates
ch VGS species in each CF patient.
Table 2
Serogroups and serotypes of S. pneumoniae isolated from adult CF patients in
this study.
Strain no. Serotype
C10 33(33F a,33A,33B,33C,33D)
C30 24(24F,24A,24B),31,40
C52 18(18F,18A,18B,18C)
C57 19(19F,19A,19B,19C)
C58 29,34,35(35F,35A,35B,35C),42,47(47F,47A)
C59 19(19F,19A,19B,19C)
C60 19(19F,19A,19B,19C)
C63 19(19F,19A,19B,19)
C69 25(25F,25A),38,43,44,45,46,48
C118 27,32(32F,32A),41(41F,41A)
C119 9(9A,9L,9N,9V)
C120 27,32(32F,32A),41(41F,41A)
C121 27,32(32F,32A),41(41F,41A)
C124 13,28(28F,28A)
C125 13,28(28F,28A)
C138 27,32(32F,32A),41(41F,41A)
C212 29,34,35(35F,35A,35B,35C),42,47(47F,47A)
C217 27,32(32F,32A),41(41F,41A)
C220 27,32(32F,32A),41(41F,41A)
a Enlarged and bold serotypes are included in the current 23-valent PPSV
vaccine.
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anginosus, S. australis, S. cristatus, S. gordonii, S. infantis, S.
mitis, S. mutans, S. oralis, S. parasanguinis, S. pneumoniae, S.
salivarius and S. sanguinis. S. agalactiae was also recovered
from one patient. The most frequently VGS organism isolated
was S. salivarius (47/190; 24.7%), followed by S. mitis (36/190;
19%), S. sanguinis (25/190; 13.2%), S. oralis (20/190; 11.0%),
S. pneumoniae (19/190; 10.0%), S. parasanguinis (16/190;
8.4%), S. infantis (11/190; 5.8%), S. gordonii (7/190; 3.7%), S.
anginosus (4/190; 2.1%), S. cristatus (2/190; 1.1%), S. australis
(1/190; 0.5%), S. mutans (1/190; 0.5%) and S. agalactiae (1/
190; 0.5%). All, but four, patients harboured at least one VGS
species, which ranged from one to five streptococcal species,
with a mean of 2.85 species per patient (Fig. 1). A representative
sequence of the rnpB gene and 16-23S rRNA ITS region for
each species has now been deposited in GenBank with the
respective accession numbers, as detailed in Table 1.
3.2. Serotyping of pneumococcal isolates
When the serotypes of the isolated pneumococci (n=19)
were further examined (see Table 2), it can be seen that 12 of
these fell immunologically outside the coverage of the 23-valent
vaccine.
3.3. Antimicrobial susceptibility
The antibiotic susceptibility of all 190 isolates was
determined by Minimum Inhibitory Concentration (MIC)
testing against penicillin, erythromycin and ciprofloxacin.
Overall, resistance to penicillin with all VGS was 73/190
(38.4%) and 167/190 (87.9%) for erythromycin. With regard to
ciprofloxacin, 27/190 (14.2%) were resistant, whilst a further
21/190 (11.1%) showed intermediate resistance, which equated
to approximately three quarters (74.7%) of isolates being fully
sensitive to this agent. Table 3 details the MIC range, geometric
MIC mean, MIC50 and MIC90 for each streptococcal species
identified against these three antibiotic agents. Table 4 details
the proportion of VGS streptococci resistant to single agents, as
well as to combinations of double agents and for all three
antibiotic agents. In comparison, 8% and 38% of VGS isolatesTable 1
Deposited accession numbers in GenBank relating to partial rpnB and 16-23S
rRNA ITS sequences for all VGS identified in this study.
Species Strain rnpB 16S-23S rRNA ITS
S. anginosus C61 GU907491 GU907504
S. australis C89 GU907492 GU907505
S. cristatus C122 GU907493 GU907506
S. gordonii C163 GU907494 GU907507
S. infantis C50 GU907495 GU907508
S. mitis C42 GU907496 GU907509
S. mutans C169 GU907497 GU907510
S. oralis C12 GU907498 GU907511
S. parasanguinis C86 GU907499 GU907512
S. pneumoniae C30 GU907500 GU907513
S. salivarius C5 GU907501 GU907514
S. sanguinis C62 GU907502 GU907515from non-CF individuals were resistant by disk susceptibility
testing to penicillin and erythromycin, respectively. None of the
non-CF VGS organisms were resistant to ciprofloxacin, but
42% showed intermediate resistance.
3.4. Determination of genetic-relatedness between VGS
ERIC-PCR produced unique genotypes with all VGS species
and also amongst isolates within each species, indicating a lack
of clonality of the VGS in the CF patient population examined.
Although, there were seven occasions that two ERIC-PCR
products from same species showed indistinguishable banding
patterns, all of these isolates were sampled from the same
patient at the same time and from the same sputum specimen.
Table 5 details the number of ERIC-PCR genotypes generated
for each VGS species.
3.5. Determination of VGS-related cytotoxicity
None of the VGS species were considered to have elicited a
cytotoxic response against the cell line tested.
4. Discussion
Recently, the employment of sophisticated molecular
techniques has allowed the identification of a diverse range of
bacterial families, genera and species in sputum from the
airways of patients with cystic fibrosis (CF), which are
generally not isolated by conventional cultural techniques in
the clinical microbiology laboratory or are isolated by such
laboratories but do not get reported, as they are considered
clinically not relevant. One such group are the viridans group
streptococci. Historically, there have been very few reports in
the literature of VGS associated with CF patients. Previously,
Table 3
MIC range, geometric MIC mean, MIC50 and MIC90 for each VGS streptococcal species identified against penicillin, erythromycin and ciprofloxacin.
Penicillin Erythromycin Ciprofloxacin
Species MIC range (μg/ml) Mean MIC50 MIC90 MIC range (μg/ml) Mean MIC50 MIC90 MIC range (μg/ml) Mean MIC50 MIC90
S. anginosus 0.015–0.125 0.05 0.03 0.125 0.06–N16 9.515 2 N16 0.5–1 0.875 1 1
S. australis 0.125 0.125 0.125 0.125 4 4 4 4 1 1 1 1
S. cristatus 0.125–0.25 0.188 0.25 0.125 0.03–4 2.015 0.03 4 2 2 2 2
S. gordonii 0.015–0.25 0.051 0.015 0.25 4–8 6.857 8 8 0.5–32 5.786 1 32
S. infantis 0.015–8 1.967 1 4 4–8 4.727 4 8 1–N64 24.64 2 64
S. mitis 0.015–8 0.507 0.06 1 0.06–N32 4.675 4 8 0.5–32 4.319 2 8
S. mutans 0.015 0.015 0.015 0.015 0.06 0.06 0.06 0.06 0.125 0.125 0.125 0.125
S. oralis 0.015–N8 2.879 0.06 N8 0.03–N16 12.31 4 N16 1–N64 17.65 4 N64
S. parasanguinis 0.03–8 1.119 0.25 4 0.06–N16 7.504 8 8 2–64 9.625 2 32
S. pneumoniae 0.015–2 0.225 0.125 0.5 0.03–N16 8.647 4 N16 0.5–8 1.711 1 4
S. salivarius 0.015–1 0.315 0.125 1 0.03–N16 15.62 8 N16 0.5–16 1.723 1 2
S. sanguinis 0.06–1 0.447 0.125 1 0.06–N16 16.25 4 N16 0.5–8 1.82 1 8
S. agalactiae 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 2 2 2 2
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6% of CF patients had a DNA fragment that was due to
organisms in the Assignation group (S. pneumoniae, S.
salivarius, S. pyogenes, S. macedonicus, S. sanguinis) and
Klepac-Ceraj et al. [10] recently reported the presence of
Streptococcus group (AF009482), Streptococcus constellatus
(AF104676) and Streptococcus gordonii (AF003931) from
oropharyngeal swabs from children with CF employing
phylochip hybridization technology.
Recently, a Canadian group has published several reports on
the clinical significance of members of the “S. milleri” or S.
anginosus group (S. constellatus, S. intermedius and S.
anginosus) [3,11]. In these reports, these workers argue that
the S. milleri group of organisms have been overlooked as
respiratory pathogens, due their difficulty in being differentiated
from the VGS, and where S. milleri infection led to malodorous
sputum in pulmonary exacerbations.
With this background and given that there have not been any
reports on VGS from patients with CF, it was the aim of this
study to specifically examine the population structure and
characteristics of resulting VGS organisms isolated from the
sputum of adult CF patients.
The majority (41/45 [91%]) of adult CF patients examined
were colonized with at least one species of VGS. In all, 12Table 4
Proportion of VGS streptococci solely resistant to each single agent, as well as
their resistance to combinations of double agents and for all three antibiotic
agents.
MIC break point criteria
Resistance pattern Number of isolates
(including intermediate resistance)
Penicillin 1
Erythromycin 71
Ciprofloxacin 1
Penicillin+Erythromycin 50
Penicillin+Ciprofloxacin 1
Erythromycin+Ciprofloxacin 25
Penicillin+Erythromycin+Ciprofloxacin 21
All susceptible 20
Total 190species of VGS were identified, including four patients (8.9%)
with S. anginosus and 10 patients (22.2%) with S. pneumoniae.
As it was not the intention of this study, at this stage, to attempt
to attribute clinical significance to these two species in these CF
patients, it has not been possible to estimate how significant
these organisms are in these patients. Nevertheless, both of
these organisms have been described as pathogens in CF
patients and hence, these two species would probably represent
the most virulent of the VGS species per se isolated in this
study. Hence, approximately one quarter of all adult CF
examined cultured a viable pneumococcus. Pneumococci are
not regarded as common respiratory pathogens in CF patients
and therefore their presence in CF airways may be akin to their
close phylogenetic neighbours, namely the VGS organisms. As
approximately 20–50% of healthy individuals may also be
colonized asymptomatically with pneumococci, it is difficult to
interpret the significance of these organisms in CF airways.
Equally, the value of pneumococcal vaccination remains
unclear in this patient group, although recommended as a
precautionary measure in such a respiratory group.
Perhaps, the most important finding of the current study is
the very high level of antibiotic resistance seen in the isolated
VGS, particularly resistance towards the macrolides.Table 5
Details of ERIC-PCR genotypes generated for each VGS species amongst the
190 VGS isolates obtained from 42 adult CF patients.
Species Patient no.
of origin
Genotype
no.
Identical
genotype no.
S. salivarius (n=47) 28 44 3
S. mitis (n=36) 19 35 1
S. sanguinis (n=25) 13 23 2
S. oralis (n=20) 14 20 0
S. pneumoniae (n=19) 10 18 1
S. parasanguinis (n=16) 10 16 0
S. infantis (n=11) 7 11 0
S.gordonii (n=7) 5 5 0
S. anginosus (n=4) 4 4 0
S. cristatus (n=2) 2 2 0
S. australis (n=1) 1 1 0
S. mutans (n=1) 1 1 0
S. agalactiae (n=1) 1 1 0
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the prophylaxis, maintenance and treatment of bacterial
respiratory pathogens causing chronic chest infections in CF
patients has important consequences for the persistence of VGS
flora of the treated patient. In order to survive, the VGS
organisms colonising the patient can evolve resistance mech-
anisms in response to the chronic use of these antibiotic agents.
What is not known at present is what resistant mechanisms do
commensal organism use and are these mechanisms potentially
transferable to hitherto sensitive pathogens. Therefore, antibi-
otic resistance within the VGS flora of CF patients potentially
may be an important reservoir of genetic material for
exacerbating antibiotic resistance in CF pathogens.
Equally, with the ability to survive intense and prolonged
antibiotic pressure, such VGS organisms may become danger-
ously poised to become potential pathogens, if (i) there is a
downward shift in the immune status of the patient e.g.
following lung transplantation, (ii) where such organisms are
genetically promiscuous in acquiring virulence determinants
from co-habiting with true pathogens and (iii) where horizontal
gene transfer events occur, leading to the acquisition of
antibiotic resistance determinants by newly colonising patho-
gens. The acquisition of virulence determinants is also a
significant cause for concern in antibiotic resistant VGS
organisms and where such commensal flora dominate. One
reason for their success is the relative plasticity of their genomes
to adapt to varying host immune responses, as well as selective
antibiotic pressure. With this genomic plasticity and the ability
to naturally transform, VGS organisms have the ability to take
up virulence determinants, which then potentially can transform
their status from commensal organism to opportunistic
pathogen to true pathogen.
Given that most CF patients are treated regularly with both
oral, iv and nebulised antibiotics for maintenance, as well as
acute pulmonary exacerbations, it is not surprising that their
commensal VGS organisms have become resistant to several
classes of antibiotics. Recently, we have shown that long-term
use of azithromycin in adult CF patients has led to a highly
macrolide resistant population of VGS isolated from patients'
sputum, in comparison to similar VGS populations originating
in non-CF patients, who were not treated with azithromycin for
long periods of time [12]. In addition, complete gene homology
in the macrolide resistance determinants, particularly erm(B)
and mef(A) is also shared with other closely-related genera,
including Gemella, Enterococcus and Granulicatella. Presence
of multiple macrolide-resistance determinants occurring at high
frequency in VGS commensal organisms is potentially
important for the CF patient, other CF patients and the non-
CF population. The presence of bacterial pathogens in CF
sputum generally reflects those bacterial genera which are
commonly associated with CF lung disease, including Pseudo-
monas aeruginosa and Burkholderia cenocepacia. Normally
these pathogens do not constitute an infection risk to the
healthy, non-CF individual. However, the presence of such
macrolide-resistance determinants in VGS organisms may be
problematic for the healthy non-CF individual, as these may act
as a reservoir of resistance determinants for other respiratorypathogens, particularly S. pneumoniae, where these commensal
flora are transmitted from the CF patient to non-CF individuals,
for example, between CF and non-CF siblings within a
household.
We subsequently wished to compare our CF VGS
population, which originated mainly from adult CF patients
taking oral azithromycin long-term, as well several courses of iv
β-lactam and oral ciprofloxacin antibiotic agents, with a VGS
population from a non-CF patient group, which had not been
exposed to long term use of macrolides or other antibiotics, in
order to access downstream consequences relating to macrolide,
as well as β-lactam and fluoroquinolone resistance in
commensal VGS flora within the CF patient population. As a
comparator, clinically non-significant and non-invasive VGS
organisms were examined in 12 consecutive patients in the
community, who were attending their primary care doctor.
These data suggests that long-term use of antibiotics in the CF
patient population may lead to high levels of antibiotic
resistance in the VGS commensal flora.
Finally, VGS organisms may be important in the CF lung, in
that they may have the ability to coaggregate with other
important CF bacterial pathogens. Coaggregation is a process
by which genetically distinct bacteria become attached to one
another via specific molecules, with the main aim of leading to
the formation of a multi-species biofilm (For a comprehensive
review on coaggregation, see Rickard et al. [13]). Oral
streptococci are widely known to be important coaggregators
in the mouth resulting in some form of mutualism for the VGS
and its coaggregating bacterial partner. Previously, Chalmers et
al. [14] described that coaggregation required a receptor
polysaccharide (RPS), which is a cell surface molecule found
on many strains of S. oralis and S. mitis [15], which mediates
coaggregation by its role as the recognition molecule for lectin-
like adhesins found on many other bacterial genera including
Actinomyces, Veillonella, and other streptococci. Six RPS types
have been identified in oral streptococci [16]. Each type is
composed of a distinct hexa- or heptasaccharide repeating unit
which contains one of two host-like disaccharide recognition
motifs, GalNAcβ1-3Gal (Gn type) or Galβ1-3GalNAc (G
type). The lectin-like adhesins on Actinomyces [17] and on
veillonellae [18] recognize the Gn and G types of RPS, whereas
certain streptococci bear GalNAc-specific adhesins that recog-
nize only the Gn types [16]. Intergeneric coaggregation of RPS-
bearing streptococci and Actinomyces [16] or veillonellae [18] is
prevalent and is thought to contribute to the formation of
pioneer multispecies communities on enamel [19,20]. Pseudo-
monas aeruginosa have been reported to produce lectin PA-IL
(galactophilic lectin, LecA) and PA-IIL (fucoseNfructose/
mannose-binding lectin, LecB), which mediate auto- as well
as hetero cell-to-cell interactions for biofilm formation and
adherence to target cells/organisms [21]. To date, intergenic
coaggregation of RPS-bearing VGS and Pseudomonas aerugi-
nosa has not yet been reported. Therefore, studies to help
elucidate a potential coaggregation effect between VGS species
and Pseudomonas aeruginosa are urgently required to help
define the role VGS as an initiator of Pseudomnas attachment
and colonization.
139Y. Maeda et al. / Journal of Cystic Fibrosis 10 (2011) 133–139The presence of VGS in the airways of CF patients may be
significant due to (i). the presence of knownVGS specieswithin the
“S. milleri” (S. anginosus group), as well as from the presence of S.
pneumoniae, which have been recently regarded as pathogenic
within the CF community, (ii). their relatively high level of
antibiotic resistance, especially with the macrolides, ciprofloxacin
and penicillin, (iii). their ability for horizontal gene transfer, which
could allow the recycling of these resistances in newly colonising
CFmicroflora, (iv). VGS's potential coaggregation events with CF
pathogens such as Staphylococcus aureus and Pseudomonas
aeruginosamay lead to initial attachment and eventual colonisation
with these pathogens and the promotion and development of
several different multispecies biofilms in the CF airways.
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